Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Semaglutide, tirzepatide, and retatrutide are incretin-based medicines studied for obesity, but the evidence does not support one universal “best” choice. In the strongest direct comparison, maximum-tolerated tirzepatide produced more average weight loss than maximum-tolerated semaglutide over 72 weeks in adults with obesity and no diabetes. Retatrutide has a larger point estimate in an indirect 2026 network analysis, yet it has not been compared directly with either drug in that analysis and its longer-term safety and regulatory status remain less established.
| Name | Best for | Key spec | Checked |
|---|---|---|---|
| Semaglutide | People who need an established GLP-1 option with U.S. FDA-labeled obesity, cardiovascular-risk and certain MASH indications | GLP-1 receptor agonist; SURMOUNT-5 comparator: 1.7 or 2.4 mg weekly; 72-week mean change −15.0 kg | November 2026 |
| Tirzepatide | Adults seeking the greatest average loss in the direct semaglutide comparison | Dual GIP/GLP-1 agonist; SURMOUNT-5 doses 10 or 15 mg weekly; 72-week mean change −22.8 kg | November 2026 |
| Retatrutide | People following an emerging investigational treatment, not a routine prescribing choice | Triple hormone-receptor agonist; 2026 network estimate −22.10% versus placebo (95% CI −25.60% to −18.60%) | November 2026 |
Which one causes more weight loss?
In a randomized head-to-head trial, tirzepatide caused more average weight reduction than semaglutide at 72 weeks. Retatrutide’s higher numerical estimate comes from an indirect network meta-analysis, so it cannot be treated as proof that retatrutide will outperform either medicine for an individual.
As an Amazon Associate I earn from qualifying purchases.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsThe direct tirzepatide-versus-semaglutide result
SURMOUNT-5 was a phase 3b, open-label, controlled trial of adults with obesity but without type 2 diabetes. Participants received once-weekly, maximum-tolerated tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The New England Journal of Medicine report found tirzepatide superior for body weight and waist circumference.
The reported least-squares mean body-weight change was −22.8 kg with tirzepatide and −15.0 kg with semaglutide. A secondary Endotext synthesis reports the corresponding percentage changes as approximately −20.2% and −13.7%, respectively. These are averages for the study population, not a promised difference for every patient.
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
Two design details matter. First, the trial was open-label, meaning participants and investigators knew which treatment was assigned. Second, it compared maximum tolerated doses, not starting doses or a casual real-world dose. Tolerability, dose escalation, adherence, insurance access and medical history can all change an individual’s result. The trial also did not include retatrutide.
What the network meta-analysis says about retatrutide
A 2026 BMJ Medicine network meta-analysis combined 58 randomized trials involving 24,214 adults with overweight or obesity without diabetes. Against placebo, it estimated mean weight changes of −22.10% for retatrutide (95% confidence interval −25.60% to −18.60%) and −19.28% for tirzepatide (95% confidence interval −20.39% to −18.16%).
Those numbers are network estimates assembled from separate trials; they are not the result of randomizing retatrutide against tirzepatide or semaglutide in the same study. The authors caution that direct head-to-head evidence is limited, newer medicines have sparse evidence “nodes,” some confidence intervals overlap, and safety follow-up is mainly short to medium term. The retatrutide point estimate is therefore promising but not a settled ranking.
How should the weight-loss numbers be compared?
The figures use different units and different comparators. SURMOUNT-5 reported least-squares mean changes in kilograms from baseline after 72 weeks in one randomized population. The network analysis reported percentage changes relative to placebo by combining many trials. A kilogram result cannot be converted into an individual percentage without knowing starting weight, and a placebo-comparative percentage is not the same as the total loss seen with active treatment.
Confidence intervals show statistical uncertainty around a group estimate, not the range that every patient should expect. Retatrutide’s interval (−25.60% to −18.60%) and tirzepatide’s interval (−20.39% to −18.16%) come from an indirect model and different trial sets. Overlap or separation in such estimates does not replace a direct randomized comparison. The most defensible conclusion is narrower: tirzepatide had the advantage over semaglutide in the specific 72-week trial, while retatrutide has a promising but indirect signal.
Duration also matters. A 72-week result describes roughly a year and four months of treatment. It does not establish what happens over several years, how a person responds after dose changes, or whether a medicine remains tolerable indefinitely. The network review specifically notes that safety follow-up for newer treatments is short to medium term.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →What is the difference between these medicines?
They all act on hormone pathways involved in appetite and glucose regulation, but they do not have identical receptor activity. Mechanism helps explain why they are studied together; it does not by itself prove superior weight loss or safety.
| Medicine | Receptor description in the cited evidence | How to interpret it |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | The most established of the three in the retrieved U.S. labeling for chronic weight management and additional indications. |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Produced greater average loss than semaglutide in the direct 72-week trial. |
| Retatrutide | Newer multi-receptor treatment; described in the cited NEJM material as a triple hormone-receptor agonist | Promising trial program, but comparative and long-term safety evidence is less mature. |
Receptor labels should not be treated as a shortcut for choosing treatment. A dual or triple agonist is not automatically more suitable for someone with a particular medical history, and a larger average reduction does not eliminate the need to evaluate contraindications, interactions, dose escalation and follow-up.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
How safe is semaglutide?
Semaglutide’s safety profile is the best documented here because the current retrieved U.S. Wegovy prescribing information gives detailed adverse effects, warnings and precautions. The label lists nausea, diarrhea, vomiting, constipation and abdominal pain among common adverse reactions.
Important warnings include pancreatitis, acute gallbladder disease, severe gastrointestinal reactions, dehydration-related acute kidney injury, and hypoglycemia risk when semaglutide is used with insulin or an insulin secretagogue. The label also discusses diabetic-retinopathy complications in people with type 2 diabetes, increased heart rate, hypersensitivity, suicidal behavior and ideation, and pulmonary aspiration during anesthesia or deep sedation.
These warnings describe issues clinicians screen for; they do not mean every patient will experience them. Persistent vomiting or diarrhea can contribute to volume depletion and kidney injury, while use with insulin or an insulin secretagogue can make low blood glucose more likely. A patient should receive product-specific instructions about symptoms, monitoring and whether another medicine needs adjustment.
Semaglutide carries a boxed warning that it caused thyroid C-cell tumors in rodents. Whether that finding applies to humans is unknown. The label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia type 2 (MEN 2).
The label says to discontinue semaglutide when pregnancy is recognized and to stop it at least two months before a planned pregnancy. It also says semaglutide delays gastric emptying and may affect absorption of oral medicines. Anyone scheduled for anesthesia or deep sedation should tell the procedural team about semaglutide. These are product-label instructions, not assumptions that should automatically be applied to retatrutide or to every formulation of another drug.
What is known about tirzepatide safety?
In the secondary Endotext summary of SURMOUNT-5, overall tolerability was comparable between tirzepatide and semaglutide, with low rates of adverse-event discontinuation in both groups. That observation comes from the trial context and a secondary clinical reference; it is not a substitute for checking the current official tirzepatide prescribing information.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
“Comparable” does not mean identical. The exact frequency of nausea, vomiting, diarrhea, constipation, abdominal symptoms, discontinuation and serious events depends on the dose, follow-up period and analysis population. A person who cannot reach a maximum tolerated dose may obtain less weight loss than the trial average, even if the medicine is effective when taken at the studied dose.
The retrieved material did not verify the current official U.S. tirzepatide label. Endotext describes U.S. indications for chronic weight management and obstructive sleep apnea in obesity, but those regulatory details should be confirmed against the current FDA label before making a treatment or coverage decision. Do not assume that a similar mechanism or similar trial tolerability means identical contraindications, drug interactions or monitoring requirements.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Is retatrutide safer or more effective?
Retatrutide cannot yet be assigned a reliable overall safety ranking against semaglutide or tirzepatide. The 2026 network review found differences in tolerability and reported low-certainty evidence suggesting higher discontinuation with retatrutide, while also emphasizing that longer-term safety evaluation is needed.
Higher discontinuation is a tolerability signal, not proof of a particular serious harm or a universal experience. It may reflect gastrointestinal symptoms, dose intensity, trial procedures or other differences between studies. The review’s evidence does not establish a complete comparison of rare harms, long-term complications or special-population risks across all three medicines.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Detailed phase 3 retatrutide safety information was not fully verifiable in the retrieved material. The current official approval status was likewise not confirmed from an official regulator or sponsor source, so retatrutide should be treated as an emerging or investigational option unless its status is independently verified for the jurisdiction and date in question.
A larger average loss does not automatically mean a medicine is safer. Gastrointestinal effects, gallbladder and pancreatic risks, interactions with diabetes medicines, pregnancy plans, anesthesia needs and a person’s prior conditions can matter more than a difference in trial averages.
Which injection has fewer side effects?
There is no defensible single winner from the available comparisons. Semaglutide has the most detailed accessible U.S. label, so more warnings are explicitly documented for it; that does not prove it causes more problems than the other medicines. The tirzepatide-versus-semaglutide trial summary describes overall tolerability as comparable, while the network review reports low-certainty evidence of higher discontinuation with retatrutide.
“Fewer side effects” also depends on which effect matters. Someone with a history of gallbladder disease may focus on a different risk than someone taking insulin, someone with kidney vulnerability, or someone preparing for anesthesia. Ask the prescriber which adverse effects are most relevant to the individual history and what symptoms require urgent advice.
Free tools Windows power users keep installed
One-click scans. No signup required.
What approvals and indications are established in the United States?
The retrieved FDA label, revised August 2025, describes semaglutide for use with reduced-calorie eating and increased physical activity to reduce excess weight and maintain weight reduction long term in eligible adults and adolescents aged 12 years or older. It also describes cardiovascular-risk reduction for adults with established cardiovascular disease and overweight or obesity, plus accelerated approval for adults with noncirrhotic MASH with moderate-to-advanced fibrosis.
The same label says coadministration with other semaglutide products or another GLP-1 receptor agonist is not recommended. That instruction should not be generalized into a self-directed combination plan involving tirzepatide or retatrutide.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
For tirzepatide, consult the current FDA label for the exact product, indication, dose escalation, contraindications and warnings. For retatrutide, verify whether an approval exists in the relevant country before treating it as an available prescription. Clinical-trial participation and commercially supplied prescriptions are not interchangeable, and an investigational compound should not be obtained from an unverified source.
How should someone choose between semaglutide and tirzepatide?
The direct trial favors tirzepatide for average weight loss in its specific population, but choosing a medicine requires matching evidence and labeling to the person’s medical situation.
- Confirm the goal and eligibility. Discuss body-mass criteria, weight-related conditions, diabetes status and whether the intended use is weight management, cardiovascular-risk reduction or another labeled indication.
- Review contraindications and high-risk history. For semaglutide, specifically discuss medullary thyroid carcinoma or MEN 2 history, pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, kidney vulnerability, pregnancy plans and upcoming anesthesia.
- List every medicine and supplement. Insulin and insulin secretagogues can increase hypoglycemia risk with semaglutide, and delayed gastric emptying can affect oral-medicine absorption. A prescriber should check the complete regimen before changing therapy.
- Discuss dose escalation and tolerability. The SURMOUNT-5 comparison used maximum tolerated doses. Starting-dose experiences cannot be used to reproduce its average outcome, and rapid self-escalation can increase adverse effects.
- Check the current label and access. Indications, supply, coverage, age limits and regulatory status can change. Use the official prescribing information for the exact product rather than relying on a comparison chart.
- Set a follow-up plan. Agree on what symptoms require urgent contact, how weight and metabolic measures will be monitored, and what to do if adverse effects prevent reaching or maintaining a tolerated dose.
How should the numbers be interpreted for one person?
Trial means describe groups, not destinies. The SURMOUNT-5 kilogram figures are least-squares means from a selected, diabetes-free population receiving maximum tolerated doses for 72 weeks. The network-analysis percentages are placebo-comparative estimates synthesized across different protocols, populations and follow-up periods.
Neither result tells an individual exactly how many kilograms will be lost, whether the person will tolerate dose escalation, or how weight will change after treatment stops. A clinician may also prioritize a labeled cardiovascular or liver indication, a contraindication profile, pregnancy planning, drug interactions or practical access over a small difference between population averages.
People with diabetes, adolescents, adults with established cardiovascular disease, and people with liver fibrosis may not match the SURMOUNT-5 eligibility criteria. Results from adults with obesity without diabetes should therefore be applied cautiously to other groups. The label for the exact product and the patient’s full history determine whether the evidence is relevant.
What evidence is still missing?
Three gaps limit a confident three-way ranking. First, the strongest direct comparison is between tirzepatide and semaglutide; it does not include retatrutide. Second, the retatrutide advantage is an indirect network estimate with sparse newer-treatment evidence and overlapping uncertainty in some comparisons. Third, the available material does not provide a complete, verified cross-drug comparison of rare and long-term harms.
Recommended Free Tools
Those gaps are especially important when a reader asks which injection has “fewer side effects.” The honest answer depends on the specific adverse effect, dose, duration, medical history and source label; current evidence does not justify naming one universal safety winner.
What is the practical bottom line?
Tirzepatide has the clearest efficacy advantage when the comparison is limited to the 72-week SURMOUNT-5 population and maximum-tolerated doses. Retatrutide’s −22.10% network estimate is an important signal, not a direct victory over either established medicine. Semaglutide has the most fully documented U.S. label in the retrieved sources, including important contraindications and precautions. The safest decision is an individualized prescribing discussion based on current labeling, health history, concomitant medicines, pregnancy plans and the maturity of the evidence—not a ranking based on one headline percentage.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
How we compared them
The comparison prioritizes randomized direct evidence over indirect estimates; records the study population, dose and duration; separates kilograms from percentage changes; reports confidence intervals and design limitations; and keeps product-label warnings distinct from class-wide assumptions. Regulatory statements are limited to the retrieved U.S. semaglutide label, with tirzepatide and retatrutide qualifications stated where current official information was not verified.
Frequently Asked Questions
Can semaglutide, tirzepatide and retatrutide be taken together?
Do not combine them on your own. The semaglutide label says coadministration with another semaglutide product or GLP-1 receptor agonist is not recommended, and there is no evidence here supporting a self-directed combination involving retatrutide.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Why do retatrutide’s percentage estimates differ from the tirzepatide-versus-semaglutide kilogram results?
They come from different evidence designs. SURMOUNT-5 directly randomized two medicines and reported least-squares kilogram changes, while the 2026 review synthesized separate placebo-controlled trials and reported network percentage estimates.
What should I bring to an appointment about one of these medicines?
Bring a complete medication list, prior pancreatitis or gallbladder problems, kidney and eye history, thyroid-cancer or MEN 2 history, diabetes treatment details, pregnancy plans and any upcoming procedure requiring anesthesia. These details can change eligibility, monitoring and the choice of product.
Does retatrutide have an FDA-approved dose for routine weight management?
The retrieved evidence did not verify a current official approval or prescribing label for retatrutide. Check the relevant regulator’s current information before considering it available outside a properly governed clinical-trial or approved-prescription setting.
How much more weight did tirzepatide produce than semaglutide in SURMOUNT-5?
At 72 weeks, the reported least-squares mean change was −22.8 kg with tirzepatide and −15.0 kg with semaglutide, a difference of 7.8 kg in that trial population. It is not a guaranteed individual difference.
The Bottom Line
Bottom line: Tirzepatide produced more average loss than semaglutide in the strongest direct trial, while retatrutide’s larger estimate remains indirect and less certain. Safety and eligibility depend on the exact label and the person’s medical history, so use these results to guide—not replace—a clinician discussion.

